HomeIndustryThere Is Nothing Like Hims & Hers Health Inc. (HIMS) Stock

There Is Nothing Like Hims & Hers Health Inc. (HIMS) Stock

SVB Leerink raised the price target for the Hims & Hers Health Inc. (NYSE:HIMS) stock from “a Mkt perform” to “an Outperform”. The rating was released on November 08, 2022, according to finviz. We previously noted in another research note published on November 08, 2022 by BofA Securities that upgraded the stock from a Neutral to a Buy with a price target of $8.50 for HIMS stock. The research report from Piper Sandler has downgraded the stock from Overweight to Neutral, with a price target set at $6. The stock was initiated by Truist, who disclosed in a research note on September 07, 2022, to Hold and set the price objective to $7. In their research brief published July 15, 2022, SVB Leerink analysts initiated the Hims & Hers Health Inc. stock to Underperform with a price target of $4.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Hims & Hers Health Inc. (NYSE:HIMS) raised 5.10% to close Monday’s market session at $7.63, higher as compared to yesterday’s close. The stock price fluctuated between $7.155 and $7.79 throughout the trading session with the volume trading being 2441713 shares, which represented a significant variation when compared to the three months average volume of 1.73 million shares. The firm’s stock price fluctuated 1.33% within the last five trades and 14.74% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 30.87% in the last 6 months and 78.27% was added to its value over the previous 3 months. HIMS stock is trading at a margin of 13.21%, 16.97% and 40.29% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


As of the close of trading, HIMS deals in the Consumer Defensive domain. The stock is trading -4.27 percent below its 52-week high and 180.51 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 55.1. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Hims & Hers Health Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -17.70 percent and the profit margin is -19.30 percent, and the company has reported a gross margin of 76.20 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $1.63 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 3.67 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 5.02, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.80 percent of Hims & Hers Health Inc. shares are owned by insiders, and 58.20 percent are held by financial institutions. Boughton Soleil, the Chief Legal Officer at Hims & Hers Health Inc. (HIMS) has sold 2,000 shares of firm on Jan 17 at a price of $7.51 against the total amount of $15020.0. In another inside trade, Boughton Soleil, Chief Legal Officer of Hims & Hers Health Inc. (NYSE:HIMS) sold 12,345 shares of the firm on Jan 03 for a total worth of $80242.0 at a price of $6.50. An inside trade which took place on Dec 19, Chief Legal Officer of Hims & Hers Health Inc. Boughton Soleil sold 13,744 shares of firm against total price of $92360.0 at the cost of $6.72 per share.



Please enter your comment!
Please enter your name here

Recent Post